IP Library Granted Patent US 10,918,664
Granted Patent B2
US 10,918,664 · App. 15/942,327 · Granted Feb 16, 2021

Chewable eye health formulation

Inventors: Marc Bellemore (Windsor, CA); Ashley V Kasurak (Windsor, CA); Paul Charlton (Windsor, CA); Megan Thomas (Windsor, CA); John Doherty (Windsor, CA); Sorin Popa (Windsor, CA)
A61K33/30A61K9/0056A61K31/047A61K31/355A61K31/375A61K33/34A61K36/28A61K36/45
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,918,664
App. No.
15/942,327
Granted
Feb 16, 2021
Kind
B2
Abstract

Risk of visual impairment including Age-Related Macular Degeneration (AMD) and cataracts increase with age. This increased risk can be caused by changes in the structure and function of the eye or changes in structures of the central nervous system that support visual perception. The present invention comprises fruit flavored, chewable formulations of supplements for reducing the risk of AMD. Chewable dosage forms of the invention are preferred over other formulations and may increase compliance in an aging population, who are more likely to require an eye health supplement and have an increased risk of experiencing dysphagia.

Claims (6)

1. A chewable tablet consisting of natural flavor, 250 mg vitamin C consisting of both ascorbic acid and sodium ascorbate, 200 international units vitamin E, 12.5 mg zinc from zinc oxide, 1.0 mg copper from copper citrate, 5 mg lutein and 1 mg zeaxanthin.

2. A method of reducing the risk of advanced age-related macular degeneration by providing a person at risk with a chewable tablet consisting of natural flavor, 250 mg vitamin C consisting of both ascorbic acid and sodium ascorbate, 200 international units vitamin E, 12.5 mg zinc from zinc oxide, 1.0 mg copper from copper citrate, 5 mg lutein and 1 mg zeaxanthin.

3. The tablet according to claim 1 wherein the natural flavor is strawberry, raspberry, or blueberry.

4. The method according to claim 2 wherein the natural flavor is strawberry, raspberry, or blueberry.

5. A method of reducing the risk of dysphagia in a person at risk of dysphagia an eye health composition complying with the recommendations of the Age Related Eye Disease Study (AREDS), by providing said person at risk with a chewable tablet consisting of natural flavor, 250 mg vitamin C consisting of both ascorbic acid and sodium ascorbate, 200 international units vitamin E, 12.5 mg zinc from zinc oxide, 1.0 mg copper from copper citrate, 5 mg lutein and 1 mg zeaxanthin.

6. The method according to claim 5 wherein the natural flavor is strawberry, raspberry, or blueberry.

Assignments (5)
SECURITY INTEREST Recorded Aug 16, 2022
From: JAMIESON LABORATORIES LTD.
To: BANK OF MONTREAL
Reel/Frame 060824/0035 →
SECURITY INTEREST Recorded Feb 14, 2020
From: JAMIESON LABORATORIES LTD.
To: BANK OF MONTREAL
Reel/Frame 051821/0159 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 16, 2019
From: JAMIESON WELLNESS,INC.
To: JAMIESON LABORATORIES, LTD
Reel/Frame 051316/0668 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 6, 2019
From: KASURAK, ASHLEY; POPA, SORIN
To: JAMIESON WELLNESS,INC.
Reel/Frame 050633/0922 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 6, 2019
From: BELLEMORE, MARC; DOHERTY, JOHN; THOMAS, MEGAN; CHARLTON, PAUL
To: JAMIESON WELLNESS,INC.
Reel/Frame 050633/0932 →
Continuity (3)
Continuation 14829728 · Aug 19, 2015
Provisional Application 62039852 · Aug 20, 2014
Related Publication 20180221408A1 · Aug 9, 2018